Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes.
Liu C, Lu JW, Wu CH, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC. · In Vivo. 2026;40:14220.
Study at a glance
Human
One patient with systemic lupus erythematosus-associated pulmonary arterial hypertension receiving ongoing medical care.
One oral hydrogen-generating capsule daily as an adjunct to existing therapy. · The capsule contained 170 mg hydrogen-enriched coral calcium; the article states an estimated hydrogen-generating capacity rather than a measured systemic dose.
Longitudinal follow-up reported in the case article.
The report describes clinical stability and changes in selected immune-cell measures after adjunctive capsule use.
A single uncontrolled case with concomitant treatment cannot establish that hydrogen caused the observed course or biomarker changes.
What kind of evidence is this?
Human
Case report
Cardiovascular and circulatory health
Other forms
Indeterminate for molecular hydrogen.
Clinical course and immune biomarkers in a single patient.
Methods
One patient with systemic lupus erythematosus-associated pulmonary arterial hypertension receiving ongoing medical care.
1 patient.
Longitudinal follow-up reported in the case article.
One oral hydrogen-generating capsule daily as an adjunct to existing therapy.
Hydrogen generated after ingestion of a capsule; not Brown's gas.
The capsule contained 170 mg hydrogen-enriched coral calcium; the article states an estimated hydrogen-generating capacity rather than a measured systemic dose.
No control; clinical course before and after adjunctive use.
Outcomes and reported result
Clinical course and regulatory and effector lymphocyte measurements.
The report describes clinical stability and changes in selected immune-cell measures after adjunctive capsule use.
The full case report, timeline, measurements and concomitant treatments were checked.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
A single uncontrolled case with concomitant treatment cannot establish that hydrogen caused the observed course or biomarker changes.
This individual case only.
JBI Case Report Checklist — preliminary
Serious concerns
No comparator and substantial confounding from disease course and concurrent therapy.
Single selected case · Co-interventions were present · Follow-up described in the report · Several outcomes were clinician- or patient-reported · No prespecified analysis plan
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 41482388 · DOI: 10.21873/invivo.14220
Free full article in PubMed Central.
PubMed record and PubMed Central full text; extraction checked 9 August 2026.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.